Companies ZEVRA THERAPEUTICS, INC.
ZEVRA THERAPEUTICS (ZVRA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me ZEVRA THERAPEUTICS, INC.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $3,445,231FY2023
- $5,355,059FY2024
- $3,782,042FY2025
CEO total pay was $3,782,042 in fiscal 2025, down from $5,355,059 in fiscal 2024.
FY2025: salary $729,167 · bonus $0 · stock awards $874,125 · option awards $1,748,250
Order ZVRA
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| R. LaDuane Clifton | $477,307 | $0 | $1,260,373 | $1,117,274 | $0 | $0 | $966,970 | $3,821,924 |
| Former Chief Financial Officer and Treasurer | ||||||||
| Neil McFarlane | 729,167 | 0 | 874,125 | 1,748,250 | 418,950 | 0 | 11,550 | 3,782,042 |
| President, Chief Executive Officer and Director | ||||||||
| Rahsaan Thompson | 466,667 | 50,000 | 272,680 | 545,360 | 178,600 | 0 | 58,067 | 1,571,374 |
| Chief Legal Officer, Secretary and Compliance Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| R. LaDuane Clifton | $3,821,924 | $1,450,273 | $2,263,257 | ↑ +2,371,651 |
| Neil McFarlane | 3,782,042 | 5,355,059 | 3,445,231 | ↓ −1,573,017 |
| Rahsaan Thompson | 1,571,374 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to motivate, reward, attract and retain high caliber management and aligns executive compensation with short- and long-term objectives, business strategy and financial performance. We generally target total compensation relative to the 50th percentile of our peer group, reflecting a 'pay for performance' philosophy.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Neil McFarlane | OPTION | 2025-02-07 | — | — | 225,000 | — | $1,748,250 |
| R. LaDuane Clifton | PSU | 2025-01-30 | — | 20,000 | — | — | 0 |
| R. LaDuane Clifton | OPTION | 2025-01-30 | — | — | 68,000 | — | 545,360 |
| R. LaDuane Clifton | RSU | 2025-01-30 | — | — | 34,000 | — | 272,680 |
| Neil McFarlane | PSU | 2025-02-07 | — | 72,500 | — | — | 0 |
| Rahsaan Thompson | PSU | 2025-01-30 | — | 20,000 | — | — | 0 |
| Neil McFarlane | RSU | 2025-02-07 | — | — | 112,500 | — | 874,125 |
| Rahsaan Thompson | OPTION | 2025-01-30 | — | — | 68,000 | — | 545,360 |
| Rahsaan Thompson | RSU | 2025-01-30 | — | — | 34,000 | — | 272,680 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Neil McFarlane | $874,125 | $0 | $1,748,250 | 0.0% |
| R. LaDuane Clifton | 272,680 | 0 | 545,360 | 0.0% |
| Rahsaan Thompson | 272,680 | 0 | 545,360 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Rahsaan Thompson | Option | 2,250 | 8.26 | — |
| Rahsaan Thompson | Option | 3,125 | 201.92 | — |
| Rahsaan Thompson | Option | 4,687 | 56.8 | — |
| Rahsaan Thompson | Option | 4,687 | 88 | — |
| Rahsaan Thompson | Option | 10,000 | 5.98 | — |
| Rahsaan Thompson | Option | 10,000 | 42.56 | — |
| Rahsaan Thompson | PSU | 20,000 | — | 179,200 |
| Rahsaan Thompson | PSU | 34,000 | — | 304,640 |
| Rahsaan Thompson | Option | 68,000 | 8.02 | — |
| Neil McFarlane | PSU | 72,500 | — | 649,600 |
| Rahsaan Thompson | Option | 82,423 | 9.06 | — |
| Rahsaan Thompson | Option | 83,486 | 7.17 | — |
| Neil McFarlane | PSU | 100,000 | — | 896,000 |
| Neil McFarlane | PSU | 112,500 | — | 1,008,000 |
| Rahsaan Thompson | PSU | 133,334 | — | 1,194,673 |
| Neil McFarlane | Option | 300,000 | 4.75 | — |
| Rahsaan Thompson | Option | 459,726 | 4.54 | — |
| Neil McFarlane | PSU | 466,667 | — | 4,181,336 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Tamara A. FavoritoIndependent · Board Chair · Audit (Chair) | $117,500 | — | $187,178 | — | — | $304,678 |
| Alicia SecorIndependent · Audit · Compensation | 5,299 | — | 259,579 | — | — | 264,878 |
| Thomas D. AndersonIndependent · Compensation (Chair) · Nominating and Corporate Governance | 65,000 | — | 187,178 | — | — | 252,178 |
| Corey WattonIndependent · Audit · Compensation | 62,500 | — | 187,178 | — | — | 249,678 |
| John B. BodeIndependent · Not standing for re-election | 59,735 | — | 187,178 | — | — | 246,913 |
| Alvin Shih, M.DIndependent · Compensation | 57,500 | — | 187,178 | — | — | 244,678 |
| Douglas W. CalderIndependent · Compensation · Nominating and Corporate Governance (Chair) | 56,814 | — | 187,178 | — | — | 243,992 |
| Wendy Dixon, Ph.DIndependent · Departed during FY | 50,516 | — | 187,178 | — | — | 237,694 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $30,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 22,500 / 15,000 / 12,500 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $474,864 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $474,864 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names ZEVRA THERAPEUTICS as a peer
Companies that benchmark against ZVRA
2 companies name ZVRA as a compensation peer
- AYTU BIOPHARMA, INCAYTUFY2026
- ORAMED PHARMACEUTICALS INC.ORMPFY2024
Each company listed discloses ZVRA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ZVRA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | ZEVRA THERAPEUTICS, INC. | 2025 | Neil McFarlane | $729,167 | $874,125 | $1,748,250 | $418,950 | $3,782,042 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 45,947,281 | 234,753 | 144,582 | 99.49% | Passed |
| 2024 | 2024-05-13 | 11,167,215 | 9,888,153 | 273,661 | 53.04% | Passed |
| 2021 | 2021-06-17 | 6,845,736 | 1,287,944 | 159,450 | 84.17% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-04 | 99.49%a |
| 2024 | 2024-05-13 | 53.04%b |
| 2021 | 2021-06-17 | 84.17%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (27 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, R. LaDuane Clifton. DEF 14A, filed 2026-04-20. Section “Executive Compensation”. As printed: 3,821,924. View filing ↗
- Section 01, Neil McFarlane. DEF 14A, filed 2026-04-20. Section “Executive Compensation”. As printed: 3,782,042. View filing ↗
- Section 01, Rahsaan Thompson. DEF 14A, filed 2026-04-20. Section “Executive Compensation”. As printed: 1,571,374. View filing ↗
- Section 03, Neil McFarlane OPTION. DEF 14A, filed 2026-04-20. Section “Outstanding Equity Awards at Fiscal Year-End Table” · grants of plan-based awards table. View filing ↗
- Section 03, R. LaDuane Clifton PSU. DEF 14A, filed 2026-04-20. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, R. LaDuane Clifton OPTION. DEF 14A, filed 2026-04-20. Section “Outstanding Equity Awards at Fiscal Year-End Table” · grants of plan-based awards table. View filing ↗
- Section 03, R. LaDuane Clifton RSU. DEF 14A, filed 2026-04-20. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Neil McFarlane PSU. DEF 14A, filed 2026-04-20. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Rahsaan Thompson PSU. DEF 14A, filed 2026-04-20. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Neil McFarlane RSU. DEF 14A, filed 2026-04-20. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Rahsaan Thompson OPTION. DEF 14A, filed 2026-04-20. Section “Outstanding Equity Awards at Fiscal Year-End Table” · grants of plan-based awards table. View filing ↗
- Section 03, Rahsaan Thompson RSU. DEF 14A, filed 2026-04-20. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 08, Tamara A. Favorito. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 304,678. View filing ↗
- Section 08, Alicia Secor. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 264,878. View filing ↗
- Section 08, Thomas D. Anderson. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 252,178. View filing ↗
- Section 08, Corey Watton. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 249,678. View filing ↗
- Section 08, John B. Bode. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 246,913. View filing ↗
- Section 08, Alvin Shih, M.D. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 244,678. View filing ↗
- Section 08, Douglas W. Calder. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 243,992. View filing ↗
- Section 08, Wendy Dixon, Ph.D. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 237,694. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-05. Item 5.07 · say-on-pay result. As reported: 99.49% (votes for as printed: 45,947,281). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-13. Item 5.07 · say-on-pay result. As reported: 53.04% (votes for as printed: 11,167,215). View filing ↗
- Section 06, 2021 vote. Form 8-K, filed 2021-06-24. Item 5.07 · say-on-pay result. As reported: 84.17% (votes for as printed: 6,845,736). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 474,864 + equity 0 + all other 0 = 474,864, summed across the director compensation table rows.
- ZEVRA THERAPEUTICS, INC. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in ZEVRA THERAPEUTICS, INC.'s own proxy. As printed: 3,782,042. View filing ↗